JP2023542092A5 - - Google Patents

Info

Publication number
JP2023542092A5
JP2023542092A5 JP2023515682A JP2023515682A JP2023542092A5 JP 2023542092 A5 JP2023542092 A5 JP 2023542092A5 JP 2023515682 A JP2023515682 A JP 2023515682A JP 2023515682 A JP2023515682 A JP 2023515682A JP 2023542092 A5 JP2023542092 A5 JP 2023542092A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
bispecific antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542092A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/075022 external-priority patent/WO2022053658A1/en
Publication of JP2023542092A publication Critical patent/JP2023542092A/ja
Publication of JP2023542092A5 publication Critical patent/JP2023542092A5/ja
Pending legal-status Critical Current

Links

JP2023515682A 2020-09-10 2021-09-10 びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 Pending JP2023542092A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063076818P 2020-09-10 2020-09-10
US63/076,818 2020-09-10
US202163164255P 2021-03-22 2021-03-22
US63/164,255 2021-03-22
PCT/EP2021/075022 WO2022053658A1 (en) 2020-09-10 2021-09-10 Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma

Publications (2)

Publication Number Publication Date
JP2023542092A JP2023542092A (ja) 2023-10-05
JP2023542092A5 true JP2023542092A5 (cg-RX-API-DMAC7.html) 2024-09-18

Family

ID=77914295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515682A Pending JP2023542092A (ja) 2020-09-10 2021-09-10 びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体

Country Status (10)

Country Link
US (2) US20230312759A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210745A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542092A (cg-RX-API-DMAC7.html)
KR (1) KR20230066392A (cg-RX-API-DMAC7.html)
AU (1) AU2021342343A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004319A2 (cg-RX-API-DMAC7.html)
CA (1) CA3192256A1 (cg-RX-API-DMAC7.html)
IL (1) IL301100A (cg-RX-API-DMAC7.html)
MX (1) MX2023002541A (cg-RX-API-DMAC7.html)
WO (1) WO2022053658A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
JP2023542290A (ja) 2020-09-10 2023-10-06 ジェンマブ エー/エス 濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
WO2022053657A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL301086A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
WO2024236031A1 (en) 2023-05-15 2024-11-21 Genmab A/S Highly purified epcoritamab compositions
TW202602494A (zh) * 2024-04-12 2026-01-16 美商建南德克公司 格菲妥單抗與化學療法之組合治療

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
IN2014CN03887A (cg-RX-API-DMAC7.html) 2011-10-27 2015-10-16 Genmab As
KR102813816B1 (ko) 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
CN107660214B (zh) * 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
EP3541843A1 (en) * 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
BR112020015052A2 (pt) 2018-02-09 2020-12-08 Genmab A/S Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes

Similar Documents

Publication Publication Date Title
JP2023542290A5 (cg-RX-API-DMAC7.html)
JP2023541860A5 (cg-RX-API-DMAC7.html)
JP2023542289A5 (cg-RX-API-DMAC7.html)
JP2023541858A5 (cg-RX-API-DMAC7.html)
JP2023542291A5 (cg-RX-API-DMAC7.html)
US12617859B2 (en) Therapeutic anti-CD40 ligand antibodies
JP2023524149A5 (cg-RX-API-DMAC7.html)
CN106795219A (zh) 抗il‑17抗体及其生产和使用的方法
JP2020504723A5 (cg-RX-API-DMAC7.html)
JP2021514973A5 (cg-RX-API-DMAC7.html)
US20240392003A1 (en) Multispecific antibodies having specificity for ror1 and cd3
JP2021524478A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2021512107A5 (cg-RX-API-DMAC7.html)
CA3176436A1 (en) Bispecific antibodies against cd3 and cd20
JP2024534602A5 (cg-RX-API-DMAC7.html)
JP2025508317A5 (cg-RX-API-DMAC7.html)
JP2024509332A5 (cg-RX-API-DMAC7.html)
RS57708B1 (sr) Antigen vezujući proteini specifični za p komponentu amiloida seruma
JP2020505350A5 (cg-RX-API-DMAC7.html)
JP2025503176A5 (cg-RX-API-DMAC7.html)
JP2025503177A5 (cg-RX-API-DMAC7.html)
IL319999A (en) Bispecific antibodies against CD3 and CD20 - for the treatment of Richter syndrome
IL314341A (en) Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
JP2023536630A5 (cg-RX-API-DMAC7.html)